Papers
4
Total Citations
143
H-Index
3
About
Dr. Tina Cascone is a leading thoracic oncologist whose research focuses on neoadjuvant immunotherapy for resectable non–small cell lung cancer (NSCLC). Her major contributions center on evaluating checkpoint inhibitors—specifically nivolumab and ipilimumab—before surgery to improve outcomes for early-stage patients. Through the landmark NEOSTAR study, she demonstrated that neoadjuvant nivolumab, alone or combined with ipilimumab, yields high pathological response rates and manageable surgical safety, with her 2022 paper on surgical outcomes accumulating 94 citations. Her 2023 work further explores chemotherapy plus dual immunotherapy, advancing the paradigm of perioperative treatment. Dr. Cascone’s research has reshaped clinical practice by providing critical evidence that neoadjuvant checkpoint blockade can be safely integrated into surgical care, offering new hope for patients with resectable NSCLC. Her achievements include leading pivotal trials and authoring commentaries that guide the field toward prime-time adoption of these strategies, making her a key voice in the immunotherapy revolution for lung cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4